Welcome to the Head and Neck Cancer Drug Development Summit
The Head and Neck Cancer Drug Development Summit is dedicated to helping optimize your clinical program in targeted, immune, and combination therapies. Designed to explore how leaders in the space are improving clinical trial design, precision oncology, patient groups, and more to beat the long-standing disparity of where head and neck cancer drugs are and where such therapies should be.
Building on recent progress and approvals for targeted and immunotherapy agents in head and neck cancer indications, register interest for this biopharma-led forum to learn from industry pioneers, network with key senior decision-makers, and identify the next therapeutic opportunities in head and neck cancers.
Evaluate the strategic importance of head & neck cancer as proof of concept indication for novel immunotherapies with Nektar Therapeutics, Ultimovacs, Sensei Bio and Vaccibody
Discover emerging immunotherapies with Istari Oncology and Cullinan Oncology
Boost immune checkpoint inhibitor activity in head & neck cancer with Ultimovacs and Immutep
Develop a targeted combinatorial therapy strategy for the treatment of head & neck cancer with AVEO Oncology and Adlai Nortye